Excelsior Biopharma Inc(TW:6496)
NT$23.65-0.20 (-0.84%)
TW:6496
Excelsior Biopharma Inc financials statements
NT$23.65
At close:-0.20 (-0.84%)
Excelsior Biopharma Inc (6496) Ratios
Excelsior Biopharma Inc Ratios
TW:6496's free cash flow for Q2 2026 was NT$-34.14M. For the 2026 fiscal year, TW:6496's free cash flow was decreased by NT$-3.70M and operating cash flow was NT$-30.44M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.95 | 3.43 | 5.92 | 3.15 | 6.12 |
| Quick Ratio | 1.19 | 2.09 | 4.61 | 2.74 | 5.31 |
| Cash Ratio | 0.50 | 1.06 | 3.55 | 1.95 | 4.41 |
| Solvency Ratio | -0.16 | -0.05 | -0.09 | -0.02 | 0.02 |
| Operating Cash Flow Ratio | -0.37 | -0.44 | -0.81 | 0.01 | 0.22 |
| Short-Term Operating Cash Flow Coverage | -0.76 | -3.58 | -5.81 | 0.02 | 1.71 |
| Net Current Asset Value | NT$ 46.46M | NT$ 186.81M | NT$ 511.22M | NT$ 935.59M | NT$ 923.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.28 | 0.24 | 0.22 | 0.22 |
| Debt-to-Equity Ratio | 0.66 | 0.44 | 0.34 | 0.31 | 0.32 |
| Debt-to-Capital Ratio | 0.40 | 0.31 | 0.25 | 0.24 | 0.24 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.10 | 0.00 | 0.00 | 0.19 |
| Financial Leverage Ratio | 1.85 | 1.59 | 1.43 | 1.42 | 1.49 |
| Debt Service Coverage Ratio | -0.55 | -0.55 | -1.30 | -0.01 | 0.47 |
| Interest Coverage Ratio | -22.43 | -9.81 | -12.74 | -5.82 | -0.22 |
| Debt to Market Cap | 0.22 | 0.10 | 0.02 | 0.25 | 0.24 |
| Interest Debt Per Share | 11.73 | 9.68 | 8.36 | 8.15 | 8.64 |
| Net Debt to EBITDA | -3.75 | -23.61 | 7.24 | -117.71 | -30.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.10% | 44.33% | 39.78% | 42.75% | 21.92% |
| EBIT Margin | -18.32% | -9.21% | -9.80% | -3.22% | -0.41% |
| EBITDA Margin | -10.34% | -0.98% | -3.81% | 0.66% | 1.73% |
| Operating Profit Margin | -19.39% | -9.13% | -10.51% | -3.77% | -0.08% |
| Pretax Profit Margin | -19.19% | -10.14% | -10.62% | -3.87% | -0.75% |
| Net Profit Margin | -20.39% | -11.45% | -11.80% | -5.03% | -1.17% |
| Continuous Operations Profit Margin | -20.39% | -11.48% | -11.80% | -5.03% | -1.17% |
| Net Income Per EBT | 106.28% | 112.95% | 111.06% | 129.87% | 156.05% |
| EBT Per EBIT | 98.96% | 111.00% | 101.01% | 102.68% | 984.10% |
| Return on Assets (ROA) | -12.34% | -6.25% | -5.77% | -1.97% | -0.85% |
| Return on Equity (ROE) | -22.78% | -9.96% | -8.24% | -2.80% | -1.27% |
| Return on Capital Employed (ROCE) | -15.66% | -5.82% | -5.75% | -2.01% | -0.06% |
| Return on Invested Capital (ROIC) | -12.96% | -5.48% | -5.45% | -1.59% | -0.06% |
| Return on Tangible Assets | -12.34% | -6.25% | -5.77% | -1.97% | -0.85% |
| Earnings Yield | -13.57% | -7.15% | -6.86% | -2.60% | -1.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.82 | 4.59 | 4.81 | 4.97 | 6.28 |
| Payables Turnover | 20.79 | 7.42 | 20.90 | 9.82 | 11.75 |
| Inventory Turnover | 1.89 | 1.58 | 2.14 | 2.04 | 5.11 |
| Fixed Asset Turnover | 2.27 | 1.97 | 1.63 | 4.00 | 7.12 |
| Asset Turnover | 0.61 | 0.55 | 0.49 | 0.39 | 0.73 |
| Working Capital Turnover Ratio | 1.99 | 1.26 | 0.86 | 0.59 | 1.01 |
| Cash Conversion Cycle | 271.39 | 260.79 | 229.16 | 215.18 | 98.50 |
| Days of Sales Outstanding | 95.51 | 79.54 | 75.94 | 73.37 | 58.10 |
| Days of Inventory Outstanding | 193.44 | 230.44 | 170.69 | 178.97 | 71.46 |
| Days of Payables Outstanding | 17.56 | 49.19 | 17.47 | 37.16 | 31.07 |
| Operating Cycle | 288.95 | 309.98 | 246.63 | 252.34 | 129.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.01 | -2.16 | -2.93 | 0.12 | 1.20 |
| Free Cash Flow Per Share | -3.81 | -7.74 | -3.71 | -0.05 | 1.14 |
| Dividend Paid and CapEx Coverage Ratio | -3.75 | -0.39 | -3.78 | 0.70 | 1.13 |
| Capital Expenditure Coverage Ratio | -3.75 | -0.39 | -3.78 | 0.70 | 19.40 |
| Operating Cash Flow Coverage Ratio | -0.26 | -0.23 | -0.36 | 0.01 | 0.14 |
| Operating Cash Flow to Sales Ratio | -0.15 | -0.12 | -0.17 | 0.01 | 0.04 |
| Free Cash Flow Yield | -13.02% | -25.85% | -12.84% | -0.18% | 3.89% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.37 | -14.00 | -14.60 | -38.61 | -86.03 |
| Price-to-Sales (P/S) Ratio | 1.50 | 1.60 | 1.72 | 1.93 | 1.02 |
| Price-to-Book (P/B) Ratio | 1.68 | 1.39 | 1.20 | 1.07 | 1.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.68 | -3.87 | -7.79 | -564.80 | 25.69 |
| Price-to-Operating Cash Flow Ratio | -9.73 | -13.84 | -9.85 | 236.48 | 24.37 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | -1.73 | -0.08 | -0.35 | 0.59 |
| Enterprise Value Multiple | -18.27 | -187.90 | -37.95 | 176.27 | 28.28 |
| Enterprise Value | 1.70B | 1.58B | 1.11B | 777.90M | 654.87M |
| EV to EBITDA | -18.27 | -187.90 | -37.95 | 176.27 | 28.28 |
| EV to Sales | 1.89 | 1.83 | 1.44 | 1.16 | 0.49 |
| EV to Free Cash Flow | -9.66 | -4.42 | -6.54 | -338.66 | 12.37 |
| EV to Operating Cash Flow | -12.24 | -15.83 | -8.27 | 141.80 | 11.73 |
| Tangible Book Value Per Share | 17.43 | 21.50 | 24.05 | 25.87 | 26.45 |
| Shareholders’ Equity Per Share | 17.43 | 21.50 | 24.05 | 25.87 | 26.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.06 | -0.13 | -0.11 | -0.30 | -0.56 |
| Revenue Per Share | 19.47 | 18.69 | 16.80 | 14.39 | 28.78 |
| Net Income Per Share | -3.97 | -2.14 | -1.98 | -0.72 | -0.34 |
| Tax Burden | 1.06 | 1.13 | 1.11 | 1.30 | 1.56 |
| Interest Burden | 1.05 | 1.10 | 1.08 | 1.20 | 1.83 |
| Research & Development to Revenue | 0.11 | 0.10 | 0.08 | 0.06 | 0.04 |
| SG&A to Revenue | 0.49 | 0.44 | 0.42 | 0.41 | 0.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 1.14 | 1.48 | -0.16 | -5.57 |
Currency in TWD
